تداخلات لوسارتان

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (نشرة إبتيفيباتيد، موانع الاستعمال)

هذه الأدوية تقلّل إطراح البوتاسيوم؛ وإضافة مكملات البوتاسيوم أو بدائل الملح قد تسبب فرط بوتاسيوم الدم، وهو يؤثر في نظم القلب. (NIH Office of Dietary Supplements, Potassium)

For coadministration with aliskiren in patients with diabetes. (نشرة لوسارتان، موانع الاستعمال)

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (نشرة أملوديبين وبينازيبريل، موانع الاستعمال)

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (نشرة بينازيبريل، موانع الاستعمال)

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin HCT in patients with diabetes. (نشرة بينازيبريل وهيدروكلوروثيازيد، موانع الاستعمال)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (نشرة تادالافيل، التحذيرات والاحتياطات)

…administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals Dosing Recommendations Doxycycline Take at… (نشرة سترات الحديديك، التداخلات الدوائية)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (نشرة كلوزابين، تحذير مؤطر)

Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. (نشرة لوسارتان، التداخلات الدوائية)

Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. (نشرة لوسارتان، التداخلات الدوائية)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (نشرة ميتولازون، التحذيرات)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (نشرة مينوكسيديل، تحذير مؤطر)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (نشرة أتوموكسيتين، التداخلات الدوائية)

Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (نشرة أتينولول، التحذيرات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (نشرة أدرينالين، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (نشرة أرمودافينيل، التحذيرات والاحتياطات)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (نشرة أريبيبرازول، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (نشرة إسمولول، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة أسينابين، التحذيرات والاحتياطات)

• Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (نشرة أفانافيل، التحذيرات والاحتياطات)

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (نشرة ألفوزوسين، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (نشرة أولانزابين، التحذيرات والاحتياطات)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة أولانزابين وفلوكسيتين، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (نشرة إيبوبروستينول، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (نشرة إيبويتين ألفا، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة إيلوبيريدون، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (نشرة بازوبانيب، التحذيرات والاحتياطات)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة باليبيريدون، التحذيرات والاحتياطات)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (نشرة برازوسين، التحذيرات)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (نشرة برومفينيرامين وسودوإيفيدرين وديكستروميثورفان، التداخلات الدوائية)

Use caution in patients taking antihypertensive medications. (نشرة بروموكريبتين، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة بريكسبيبرازول، التحذيرات والاحتياطات)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (نشرة بريمونيدين، التداخلات الدوائية)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (نشرة بنتوكسيفيلين، التداخلات الدوائية)

Amphetamines may decrease the hypotensive effect of antihypertensives. (نشرة بنزفيتامين، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (نشرة بورتيزوميب، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (نشرة بيسوبرولول، التحذيرات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (نشرة تاكروليموس، التحذيرات والاحتياطات)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (نشرة ترازودون، التحذيرات والاحتياطات)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (نشرة تستوستيرون، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (نشرة تولفابتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (نشرة تيرازوسين، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (نشرة دروسبيرينون وإيثينيل إستراديول، التحذيرات والاحتياطات)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (نشرة دولوكسيتين، التحذيرات والاحتياطات)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (نشرة ديثيل بروبيون، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

• Antihypertensive Drugs: Monitor blood pressure. (نشرة ديكسميثيل فينيدات، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (نشرة ريسبيريدون، التحذيرات والاحتياطات)

However, rifampin has been shown to decrease the AUC of losartan and its active metabolite by 30% and 40%, respectively. (نشرة لوسارتان، التداخلات الدوائية)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (نشرة ريوسيغوات، التحذيرات والاحتياطات)

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة زيبراسيدون، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (نشرة سورافينيب، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Initiate and/or adjust antihypertensive therapy as appropriate. (نشرة سونيتينيب، التحذيرات والاحتياطات)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (نشرة سيكلوبنزابرين، التداخلات الدوائية)

Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (نشرة سيكلوسبورين، التداخلات الدوائية)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (نشرة سيلدينافيل، التحذيرات والاحتياطات)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (نشرة سيلودوسين، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (نشرة فاردينافيل، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Fluconazole, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of losartan by approximately 70% following multiple doses. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (نشرة فينلافاكسين، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (نشرة فينيلزين، التحذيرات)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (نشرة كاربيدوبا، التداخلات الدوائية)

Antihypertensive drugs: May cause symptomatic postural hypotension. (نشرة كاربيدوبا وليفودوبا، التداخلات الدوائية)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (نشرة كارفيديلول، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (نشرة كاريبرازين، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (نشرة كويتيابين، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (نشرة لوراسيدون، التحذيرات والاحتياطات)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Lithium: Risk of lithium toxicity. (نشرة لوسارتان، التداخلات الدوائية)

However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (نشرة مودافينيل، التحذيرات والاحتياطات)

Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (نشرة لوسارتان، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

Antihypertensive Drugs: Monitor blood pressure. (نشرة ميثيل فينيدات، التداخلات الدوائية)

REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (نشرة ميرتازابين، التحذيرات والاحتياطات)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (نشرة ميكاميلامين، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (نشرة نياسين، التداخلات الدوائية)

Antihypertensives: Possible additive hypotensive effects. (نشرة نيتروغليسرين، التداخلات الدوائية)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (نشرة نيموديبين، التداخلات الدوائية)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (نشرة لوسارتان، التحذيرات والاحتياطات)

NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (نشرة لوسارتان، التداخلات الدوائية)

In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (نشرة إسراديبين، التداخلات الدوائية)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (نشرة إيفيدرين، التداخلات الدوائية)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (نشرة إيكاتيبانت، التداخلات الدوائية)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (نشرة بروتريبتيلين، التحذيرات)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (نشرة بروكلوربيرازين، الاحتياطات)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (نشرة بوتورفانول، التحذيرات)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (نشرة تريفلوبيرازين، الاحتياطات)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (نشرة ديسوجيستريل وإيثينيل إستراديول، التحذيرات)

This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (نشرة ديسيبرامين، التحذيرات)

Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

Renin-Angiotensin-Aldosterone System Inhibitors 7.3 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (نشرة سترات البوتاسيوم، التداخلات الدوائية)

Losartan, glipizide and levothyroxine did not show any changes in exposure when co-administered with LOKELMA. (نشرة سيكلوسيليكات الزركونيوم الصوديوم، التداخلات الدوائية)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (نشرة كلوربرومازين، التحذيرات)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (نشرة كلوريد البوتاسيوم، التداخلات الدوائية)

Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (نشرة ميتوبرولول، التحذيرات والاحتياطات)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (نشرة ميثيل دوبا، التداخلات الدوائية)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (نشرة ميكسيليتين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (نشرة نيتروبروسيد، التحذيرات)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (نشرة نيسولديبين، التداخلات الدوائية)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (نشرة هيدرالازين، التداخلات الدوائية)

The AUC of active metabolite following oral losartan was not affected by erythromycin, an inhibitor of P450 3A4, but the AUC of losartan was increased by 30%. (نشرة لوسارتان، التداخلات الدوائية)

Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (نشرة لوسارتان، التداخلات الدوائية)

Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (نشرة لوسارتان، التداخلات الدوائية)

Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (نشرة لوسارتان، التداخلات الدوائية)

Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (نشرة لوسارتان، التداخلات الدوائية)

Conversion of losartan to its active metabolite after intravenous administration is not affected by ketoconazole, an inhibitor of P450 3A4. (نشرة لوسارتان، التداخلات الدوائية)

Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (نشرة لوسارتان، التداخلات الدوائية)